ASPG and acute lymphoblastic leukemia: Furthermore, prospective data from the NOPHO ALL2008 trial in pediatric patients with ALL have demonstrated that lower doses of asparaginase can significantly reduce toxicity while preserving efficacy and survival outcomes [21].